Fzata, Inc. Welcomes Gianna Arnold to Its Board of Directors as Independent Member Fzata, Inc. has appointed Gianna Arnold as a new independent member of its board, bringing extensive experience in biopharma legal affairs and corporate strategy.

Fzata, Inc. Welcomes Gianna Arnold to Its Board of Directors as Independent Member #United_States #Halethorpe #Fzata #Gianna_Arnold #BioPYM

Fzata Inc. Set to Showcase Innovations at BIO International Convention 2025 Fzata, Inc. is gearing up to attend the BIO International Convention 2025 to explore strategic partnerships for its groundbreaking IBD treatment.

Fzata Inc. Set to Showcase Innovations at BIO International Convention 2025 #United_States #Boston #IBD_treatment #Fzata #BIO_Convention

Fzata's FZ002: A New Hope in Treating C. difficile Infections Fzata, Inc. has partnered with the NIH to launch a Phase 1 trial for FZ002, a novel oral therapy targeting C. difficile, promising safer treatment options.

Fzata's FZ002: A New Hope in Treating C. difficile Infections #United_States #Halethorpe #C._difficile #Fzata #FZ002